Cullinan Therapeutics IncNASDAQ:CGEM
- LAST PRICE12.7700
- TODAY'S CHANGE (%)0.2300 (1.8341%)
- Bid / Lots12.3500/ 2
- Ask / Lots14.3500/ 1
- Open / Previous Close12.4900 / 12.5400
- Day Range
- 52 Week Range
- Volume354,377
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CGEM |
|---|---|---|
| 09:32 ET | 2522 | 12.49 |
| 09:33 ET | 17756 | 12.555 |
| 09:35 ET | 9100 | 12.585 |
| 09:37 ET | 19785 | 12.755 |
| 09:39 ET | 100 | 12.85 |
| 09:44 ET | 1036 | 12.67 |
| 09:46 ET | 1692 | 12.84 |
| 09:48 ET | 2000 | 12.9 |
| 09:50 ET | 700 | 12.9 |
| 09:51 ET | 400 | 12.99 |
| 09:55 ET | 1470 | 12.89 |
| 09:57 ET | 383 | 12.9554 |
| 10:00 ET | 1000 | 12.82 |
| 10:02 ET | 600 | 12.86 |
| 10:06 ET | 100 | 12.785 |
| 10:09 ET | 172 | 12.83 |
| 10:11 ET | 8705 | 12.65 |
| 10:13 ET | 986 | 12.64 |
| 10:18 ET | 400 | 12.7 |
| 10:20 ET | 200 | 12.71 |
| 10:22 ET | 8942 | 12.67 |
| 10:24 ET | 1500 | 12.655 |
| 10:26 ET | 200 | 12.69 |
| 10:27 ET | 300 | 12.67 |
| 10:29 ET | 100 | 12.66 |
| 10:31 ET | 400 | 12.715 |
| 10:33 ET | 1389 | 12.75 |
| 10:36 ET | 1075 | 12.75 |
| 10:38 ET | 100 | 12.72 |
| 10:40 ET | 1950 | 12.77 |
| 10:42 ET | 3027 | 12.91 |
| 10:44 ET | 450 | 12.94 |
| 10:45 ET | 2252 | 12.9999 |
| 10:47 ET | 800 | 12.97 |
| 10:49 ET | 1240 | 12.9525 |
| 10:56 ET | 200 | 13.01 |
| 10:58 ET | 100 | 13 |
| 11:00 ET | 200 | 13 |
| 11:02 ET | 701 | 12.98 |
| 11:03 ET | 200 | 13.05 |
| 11:05 ET | 229 | 13.185 |
| 11:09 ET | 100 | 13.2 |
| 11:12 ET | 7446 | 12.98 |
| 11:14 ET | 1100 | 12.9009 |
| 11:18 ET | 331 | 12.965 |
| 11:20 ET | 2000 | 12.95 |
| 11:21 ET | 4127 | 12.86 |
| 11:23 ET | 295 | 12.8 |
| 11:25 ET | 700 | 12.855 |
| 11:27 ET | 583 | 12.88 |
| 11:30 ET | 200 | 12.905 |
| 11:32 ET | 1000 | 12.89 |
| 11:36 ET | 300 | 12.91 |
| 11:39 ET | 475 | 12.89 |
| 11:41 ET | 252 | 12.9 |
| 11:43 ET | 405 | 12.885 |
| 11:45 ET | 200 | 12.885 |
| 11:48 ET | 111 | 12.92 |
| 11:50 ET | 200 | 12.9 |
| 11:52 ET | 100 | 12.85 |
| 11:57 ET | 145 | 12.91 |
| 11:59 ET | 400 | 12.895 |
| 12:03 ET | 200 | 12.86 |
| 12:06 ET | 2674 | 12.93 |
| 12:08 ET | 1849 | 13.01 |
| 12:10 ET | 500 | 13.05 |
| 12:12 ET | 200 | 13.045 |
| 12:15 ET | 1333 | 13.07 |
| 12:17 ET | 513 | 13.04 |
| 12:19 ET | 107 | 13.08 |
| 12:21 ET | 200 | 13.04 |
| 12:24 ET | 100 | 13.03 |
| 12:26 ET | 200 | 13.03 |
| 12:30 ET | 620 | 13.04 |
| 12:33 ET | 100 | 13.07 |
| 12:35 ET | 1488 | 12.99 |
| 12:37 ET | 1103 | 12.94 |
| 12:39 ET | 100 | 12.93 |
| 12:42 ET | 100 | 12.95 |
| 12:44 ET | 101 | 12.92 |
| 12:46 ET | 194 | 12.94 |
| 12:50 ET | 400 | 12.96 |
| 12:51 ET | 300 | 13 |
| 12:55 ET | 600 | 12.965 |
| 01:00 ET | 257 | 12.95 |
| 01:04 ET | 200 | 12.93 |
| 01:06 ET | 452 | 12.955 |
| 01:08 ET | 265 | 12.92 |
| 01:09 ET | 200 | 12.92 |
| 01:11 ET | 658 | 12.89 |
| 01:13 ET | 100 | 12.93 |
| 01:18 ET | 1653 | 12.9 |
| 01:20 ET | 300 | 12.91 |
| 01:22 ET | 100 | 12.89 |
| 01:24 ET | 300 | 12.895 |
| 01:26 ET | 101 | 12.86 |
| 01:29 ET | 1200 | 12.8684 |
| 01:31 ET | 200 | 12.885 |
| 01:42 ET | 1044 | 12.887 |
| 01:44 ET | 200 | 12.9 |
| 01:47 ET | 599 | 12.94 |
| 01:54 ET | 573 | 12.9 |
| 01:56 ET | 100 | 12.92 |
| 02:00 ET | 200 | 12.88 |
| 02:02 ET | 100 | 12.9 |
| 02:07 ET | 714 | 12.895 |
| 02:09 ET | 1447 | 12.89 |
| 02:12 ET | 784 | 12.87 |
| 02:14 ET | 650 | 12.88 |
| 02:16 ET | 600 | 12.9 |
| 02:20 ET | 327 | 12.86 |
| 02:21 ET | 100 | 12.85 |
| 02:23 ET | 400 | 12.86 |
| 02:27 ET | 200 | 12.85 |
| 02:30 ET | 253 | 12.84 |
| 02:34 ET | 203 | 12.83 |
| 02:36 ET | 625 | 12.845 |
| 02:39 ET | 698 | 12.81 |
| 02:48 ET | 100 | 12.82 |
| 02:52 ET | 376 | 12.82 |
| 02:56 ET | 924 | 12.83 |
| 02:57 ET | 100 | 12.825 |
| 03:01 ET | 300 | 12.85 |
| 03:03 ET | 500 | 12.91 |
| 03:08 ET | 2920 | 12.8 |
| 03:12 ET | 100 | 12.87 |
| 03:14 ET | 594 | 12.89 |
| 03:17 ET | 100 | 12.9 |
| 03:19 ET | 700 | 12.93 |
| 03:21 ET | 1320 | 12.875 |
| 03:24 ET | 400 | 12.86 |
| 03:26 ET | 329 | 12.89 |
| 03:30 ET | 200 | 12.86 |
| 03:32 ET | 626 | 12.85 |
| 03:33 ET | 200 | 12.82 |
| 03:35 ET | 310 | 12.85 |
| 03:37 ET | 700 | 12.79 |
| 03:39 ET | 480 | 12.84 |
| 03:42 ET | 436 | 12.84 |
| 03:44 ET | 200 | 12.85 |
| 03:46 ET | 665 | 12.84 |
| 03:48 ET | 1020 | 12.905 |
| 03:50 ET | 1325 | 12.89 |
| 03:51 ET | 1536 | 12.9038 |
| 03:53 ET | 1706 | 12.89 |
| 03:55 ET | 21499 | 12.8 |
| 03:57 ET | 3288 | 12.8 |
| 04:00 ET | 61606 | 12.77 |
Nov 14, 2024
Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024, from 10:01AM ET on Thursday Nov 14, 2024 by Dow Jones
10:01AM ET on Thursday Nov 14, 2024 by Dow Jones
Nov 7, 2024
Press Release: Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results, from 7:01AM ET on Thursday Nov 07, 2024 by Dow Jones
7:01AM ET on Thursday Nov 07, 2024 by Dow JonesCullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results, from 7:01AM ET on Thursday Nov 07, 2024 by Dow Jones
7:01AM ET on Thursday Nov 07, 2024 by Dow Jones
Nov 5, 2024
Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference, from 7:00AM ET on Tuesday Nov 05, 2024 by Dow Jones
7:00AM ET on Tuesday Nov 05, 2024 by Dow Jones
Nov 4, 2024
Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024, from 7:00AM ET on Monday Nov 04, 2024 by Dow Jones
7:00AM ET on Monday Nov 04, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Cullinan Therapeutics Inc | 730.2M | -4.4x | --- |
Oruka Therapeutics Inc | 726.2M | -3.1x | --- |
CARGO Therapeutics Inc | 747.0M | -5.0x | --- |
Tectonic Therapeutic Inc | 709.6M | -3.4x | --- |
Erasca Inc | 763.4M | -3.4x | --- |
Oculis Holding AG | 616.2M | -7.7x | --- |
Company Information
Cullinan Therapeutics, Inc., formerly Cullinan Oncology, Inc., is a biopharmaceutical company focused on developing modality-agnostic targeted therapies. It has a portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its pipeline includes CLN-619, CLN-978, Zipalertinib (CLN-081/TAS6417), CLN-049, CLN-418, and CLN-617. Its lead unpartnered program, CLN-619, is a humanized lgG1 monoclonal antibody (mAb) that binds to the stress induced ligands MICA and MICB (MICA/B), which are expressed on a variety of solid tumors and hematologic malignancies. CLN-978 is a novel, highly potent, half-life extended CD19xCD3 bispecific T cell engager construct. CLN-081/TAS6417 is a novel, orally available, covalent inhibitor of mutant epidermal growth factor receptor (EGFR). CLN-049 is a FLT3xCD3 T cell engaging bispecific antibody. CLN-418 is a B7H4 x 4-1BB bispecific immune activator.
Contact Information
- Headquarters
- One Main Street, Suite 1350CAMBRIDGE, MA, United States 02142
- Phone
- 617-410-4650
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Anthony Rosenberg
- President, Chief Executive Officer, Director
- Nadim Ahmed
- Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer
- Mary Fenton
- Chief Scientific Officer
- Jennifer Michaelson
- Chief Legal and Compliance Officer, Company Secretary
- Jacquelyn Sumer
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $730.2M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 58.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.19 |
EPS | $-2.88 |
Book Value | $10.58 |
P/E Ratio | -4.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
